RecruitingCataractGlaucomaOcular Hypertension
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
Eligible age
22+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Sponsor: SpyGlass Pharma, Inc.
You may qualify if…
- ✓ Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension
- ✓ Planned removal of cataract
- ✓ Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception
You may not qualify if…
- ✕ Uncontrolled systemic disease
- ✕ History of incisional/refractive corneal surgery
- ✕ Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma
- ✕ History of incisional glaucoma surgery or intraocular injections
- ✕ Other ocular diseases, pathology, or conditions
Where it's recruiting
Texas
San Antonio
Source: ClinicalTrials.gov · NCT07218796 · last updated 2025-10-20